摘要
目的:观察艾司西酞普兰与文拉法辛缓释剂治疗广泛性焦虑障碍的疗效和安全性。方法:将74例符合《国际疾病与相关健康问题统计分类(ICD)第10版》(ICD-10)广泛性焦虑障碍的患者随机分成艾司西酞普兰组(n=38)和文拉法辛缓释剂组(n=36),治疗持续8周,用汉密尔顿焦虑量表(HAMA)评定患者焦虑症状及疗效,用汉密尔顿抑郁量表(HAMD)评定患者的抑郁症状,同时用不良反应量表(TESS)和实验室检查评估治疗安全性。结果:治疗1周末两组HAMA评分开始明显下降(P<0.01),第1、2、4周末艾司西酞普兰组HAMA减分率明显高于文拉法辛缓释剂组(P<0.05),但是第8周末两组的减分率无统计学差异(P>0.05)。8周末两组的治愈率分别为60.5%和66.7%,有效率分别为78.9%和86.1%,文拉法辛缓释剂组显著高于艾司西酞普兰组(P<0.01)。8周末两组HAMD评分较治疗前也均有明显下降(P<0.01)。两组不良反应差异无统计学意义(P>0.05)。结论:文拉法辛缓释剂治疗广泛性焦虑总体疗效优于艾司西酞普兰,但是艾司西酞普兰起效快于文拉法辛缓释剂,两者安全性无明显差异。
AIM： To observe the efficacy and safety of escitalopram and venlafaxine on the treatment of generalized anxiety disorder（GAD） patients.METHODS： 74 patients who met the ICD-10 criteria for GAD were divided into escitalopram group（n=38） and venlafaxine group（n=36） randomly.The trial lasted 8 weeks.The anxiety status and efficacy was evaluated with HAMA at the baseline,1st,2th,4th and 8th weekend respectively while the depression status was evaluated by HAMD,and the safety was evaluated by TESS and laboratory examination.RESULTS：The HAMA scores of both group declined significantly by the end of 1st week（P0.01）,and the reduction of HAMA scores in the escitalopram group were larger than those in venlafaxine group at the end of 1st,2th and 4th weekend（P0.05）,while there were no significant difference between the two groups at the end of 8th weekend（P0.05）.There were significant difference within the remission rate 60.5% vs 66.7%,and response rate 78.9% vs 86.1% between the two groups（P0.01）.The HAMD scores decreased significantly after 8 weeks treatment in both groups（P0.01）.The side effects of both groups had no significant difference（P0.05）.CONCLUSION： Either escitalopram or venlafaxine would be effective for GAD,but it seemed that venlafaxine was more effective than escitalopram,and escitalopram responses faster,while the safety was similar.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2012年第10期1167-1171,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
湖州市科技局攻关计划项目(2010GS07)
